Get the Stockscreener App
133.26
2.25%
-3.07
After Hours:
133.26
Insmed Inc stock is traded at $133.26, with a volume of 1.56M.
It is down -2.25% in the last 24 hours and down -19.17% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$136.33
Open:
$135.65
24h Volume:
1.56M
Relative Volume:
0.70
Market Cap:
$28.76B
Revenue:
$606.42M
Net Income/Loss:
$-1.28B
P/E Ratio:
-20.81
EPS:
-6.403
Net Cash Flow:
$-997.58M
1W Performance:
-1.41%
1M Performance:
-19.17%
6M Performance:
-29.72%
1Y Performance:
+83.45%
1-Day Range:
$132.39
$137.62
1-Week Range:
$132.39
$139.54
52-Week Range:
$63.81
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
133.26 | 28.76B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
MSN Money - MSN
Wealthfront Advisers LLC Takes $1.74 Million Position in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Shares Bought by Danske Bank A S - MarketBeat
Raymond James Starts Insmed (INSM) at Outperform, Citing Limited Competition - Yahoo Finance UK
Vanguard’s Larger Passive Stake Puts Insmed’s Volatile Story In Focus - Yahoo Finance
Earnings Preview: Insmed to Report Financial Results Pre-market on May 07 - Moomoo
Jennison Associates LLC Decreases Position in Insmed, Inc. $INSM - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Purchases New Position in Insmed, Inc. $INSM - MarketBeat
Insmed executives line up two healthcare investor conference talks in May - Stock Titan
Insmed (INSM) expected to beat earnings estimates: Can the stock move higher? - MSN
Vanguard (NASDAQ: INSM) reports 11.5M Insmed shares, 5.34% stake - Stock Titan
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Insmed (INSM) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Book value per share of Insmed Incorporated – LSE:0JAV - TradingView
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Insmed drops skin disorder candidate after mid-stage trial setback - MSN
Vanguard Group Inc. Has $3.67 Billion Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: United Therapeutics (UTHR), Insmed (INSM) and MannKind (MNKD) - The Globe and Mail
Pictet Asset Management Holding SA Sells 181,864 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Stock Hits Day Low of $134.72 Amid Price Pressure - Markets Mojo
Non-Cystic Fibrosis Bronchiectasis Pipeline Set for Significant Expansion by 2026 with 12+ Therapies and Robust Clinical Progress from Haisco Pharmaceutical, CSL Behring, Insmed, Zambon | DelveInsight - Barchart
Insmed, Inc. (NASDAQ:INSM) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Insmed ends Brinsupri development in skin disease post study failure - MSN
Insmed, Inc. $INSM Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Insmed (INSM) Slips 6% as Investors Continue to Digest Failed HS Trial and Reposition Ahead of Upcoming Earnings - Moomoo
Insmed (INSM) slips 6% as investors continue to digest failed HS trial and reposition ahead of upcoming earnings - Quiver Quantitative
Insmed (NASDAQ:INSM) Trading Down 5.9%What's Next? - MarketBeat
The ESG Growth Portfolio's Insmed Inc(INSM) Holding History - GuruFocus
Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models - Yahoo Finance
How The Insmed (INSM) Investment Story Is Shifting On Brinsupri And ENCORE Developments - Yahoo Finance
KLP Kapitalforvaltning AS Has $12.88 Million Stock Position in Insmed, Inc. $INSM - MarketBeat
The 'worst-case scenario' — why Insmed just reversed after a 181% six-month sprint - MSN
Insmed’s TPIP Extension Study Completion: What Long-Term PH-ILD Data Could Mean for INSM Investors - TipRanks
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 - Financial Times
What Insmed will cover May 7: Q1 results and a business update - Stock Titan
INSMED EV-to-OCF: -30.50 | Fairly Valued - GuruFocus
Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Insmed, Inc. $INSM - MarketBeat
M&T Bank Corp Grows Stock Position in Insmed, Inc. $INSM - MarketBeat
Asset Management One Co. Ltd. Purchases Shares of 80,887 Insmed, Inc. $INSM - MarketBeat
Insmed Inc stock (US4576693075): Is the rare disease pipeline strong enough to unlock new upside? - AD HOC NEWS
Insmed Incorporated (INSM) Stock Analysis: Potential 47% Upside With Strong Buy Ratings - DirectorsTalk Interviews
Mirae Asset Global Investments Co. Ltd. Acquires 69,410 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Stock Hits Day Low of $135.73 Amid Price Pressure - Markets Mojo
GF Fund Management CO. LTD. Grows Stake in Insmed, Inc. $INSM - MarketBeat
KBC Group NV Buys 24,396 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Reiterates by Roth Capital -- Price Target Maintained at $2 - GuruFocus
Insmed chair and CEO William Lewis sells $1.54m in stock - Investing.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
INSMED (INSM) CEO exercises options and sells 10,699 shares under 10b5-1 plan - Stock Titan
Roth Mkm Reaffirms "Buy" Rating for Insmed (NASDAQ:INSM) - MarketBeat
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - Moomoo
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Apr 16 '26 |
Sale |
143.97 |
10,699 |
1,540,332 |
301,185 |
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):